Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

From the research standpoint, there is a need to understand the barriers to long-term adherence, whether that’s related to ...

However, tirzepatide, a long-acting glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like ...

In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with ...

McGuire and colleagues wrote about the SELECT trial and recent data analyses in July in Nature Medicine and what ... cause was also 20% lower. “GLP-1/GIP can be viewed as agents that ...

According to the WHO, over 64 million adults and 300,000 children and adolescents in Europe are currently living with ...

A new guideline released on World Diabetes Day will give GPs and other health professionals positive recommendations for optimal diabetes management ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist to reach the market, but has also benefitted from supply constraints from Novo Nordisk's GLP-1 agonist ...